Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 428 participants.
Also called NCT02432833
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 428 participants
- Sponsor
- Registry
-
NCT02432833 -
2014-004314-29
-
- Other papers using this trial's data
- Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in de novo Kidney Transplant Patients Across Europe
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Italy
- Registry status
- Completed
Technical summary
Registry record NCT02432833. Randomized; no masking; primary purpose treatment. Start 2015-05 (registry gives no type); primary completion 2017-01-24 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients
- Acronym
- STEADY
- Condition
- End Stage Renal Disease
- Intervention (Drug)
- ENVARSUS®
- Intervention (Drug)
- PROGRAF®
- Intervention (Drug)
- ADVAGRAF®
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
Record details
- Record id
cardio:ct-nct02432833- Content hash
3d98c383685c71476d6221860bb2cc2441f1a718de653b7477870798ebc8dc73